$KYNB News
Last published 2mo ago
- 2mo agoKYNBKyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireSAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced that the company’s management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference
- 2mo agoKYNBKyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing ObligationGlobeNewswireCompany reduces the maximum aggregate payments under its royalty financing agreement from $125 million to $65 millionCompany accelerated payment of $42.6 million upfront, bringing total payments made to date to $50
- 3mo agoKYNBKyntra Bio Second Quarter 2026 Earnings Conference Call - KYNTRA BIO INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Kentra Bio second quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer sessi
- 3mo agoKYNBKyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on
- 3mo agoKYNBKyntra Bio to Report Second Quarter 2026 Financial ResultsGlobeNewswireSAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference
- 5mo agoKYNBKyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic SyndromesGlobeNewswireIn a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to
- 6mo agoKYNBKyntra Bio First Quarter 2026 Earnings Conference Call - KYNTRA BIO INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Kentra Bio First Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, we'll open up for
- 6mo agoKYNBKyntra Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis
- 6mo agoKYNBKyntra Bio to Report First Quarter 2026 Financial ResultsGlobeNewswireSAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on
- 7mo agoKYNBKyntra Bio to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane
- 8mo agoKYNBKyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswirePhase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for
- 8mo agoFGENKYNBKyntra Bio to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close.
- 8mo agoFGENKYNBKyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026GlobeNewswireFG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a
- 8mo agoFGENKYNBKyntra Bio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), today announced that the company's management will participate in the following investor conferences: